Latest posts
-
SELLAS Advances Blood Cancer Treatment with “Tremendous Therapeutic Promise”
October 11, 2023 SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has reported two significant milestones this week as it pursues development of its drug candidate, SLS009 for hematological malignancies. “SLS009 is a novel and highly selective CDK9 inhibitor which, to date, has shown tremendous therapeutic promise across multiple blood cancers.” Angelos Stergiou, MD, ScD h.c.,
-
BioAdaptives Announces Nationwide Launch of Lung Fortress™ Natural Supplement
Lung Fortress is a new potent, derivative natural supplement to support pulmonary health amid rising concerns for seasonal increases in respiratory problems LAS VEGAS, NV, October 10, 2023 – BioAdaptives, Inc. (OTC: BDPT), a leading formulator and distributor of innovative, all-natural dietary supplements, today announces the launch of Lung Fortress™, a robust, all-natural supplement formula designed
-
SELLAS SLS009 Phase 1 Clinical Study Successfully Achieves All Primary and Secondary Endpoints
September 22, 2023 Late-stage biopharmaceutical company, SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has announced positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from its Phase 1 dose-escalation trial of its CDK9 inhibitor, SLS009 (GFH009). We are excited to share strong topline data from the Phase 1 trial of SLS009 in lymphoma patients. The